<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OPINION STATEMENT: Considerable clinical experience with <z:chebi fb="0" ids="49200">proton pump inhibitors</z:chebi> (<z:chebi fb="4" ids="53266">PPIs</z:chebi>) attests to their efficacy and safety in short-and long-term therapy for <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>) in erosive <z:hpo ids='HP_0100633'>esophagitis</z:hpo> and endoscopy-negative (NERD) patients </plain></SENT>
<SENT sid="1" pm="."><plain>One alternative to continuous <z:chebi fb="4" ids="53266">PPI</z:chebi> maintenance is <z:chebi fb="4" ids="53266">PPI</z:chebi> therapy administered noncontinuously (eg, "on demand") </plain></SENT>
<SENT sid="2" pm="."><plain>Qualities of good <z:chebi fb="4" ids="53266">PPI</z:chebi> therapy for such a modality should include fast and sustained acid suppression </plain></SENT>
<SENT sid="3" pm="."><plain>The newer-generation <z:chebi fb="4" ids="53266">PPI</z:chebi> <z:chebi fb="0" ids="50275">esomeprazole</z:chebi> has provided greater acid inhibition </plain></SENT>
<SENT sid="4" pm="."><plain>Randomized controlled clinical trials comparing on-demand <z:chebi fb="4" ids="53266">PPI</z:chebi> versus placebo or versus continuous <z:chebi fb="4" ids="53266">PPI</z:chebi> therapy in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> patients have shown that on-demand therapy with currently available <z:chebi fb="4" ids="53266">PPIs</z:chebi> (<z:chebi fb="0" ids="50275">esomeprazole</z:chebi> in particular) appears to be effective in the long-term management of patients with NERD or mild <z:hpo ids='HP_0100633'>esophagitis</z:hpo> and uninvestigated forms of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>, who make up the overwhelming majority of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>This is because it is safe and provides adequate symptom control and sustains quality of life </plain></SENT>
<SENT sid="6" pm="."><plain>However, it is not indicated in patients with severe erosive <z:hpo ids='HP_0100633'>esophagitis</z:hpo> or with complicated <z:hpo ids='HP_0100633'>esophagitis</z:hpo> (ie, <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> or stricture) </plain></SENT>
<SENT sid="7" pm="."><plain>On-demand <z:chebi fb="4" ids="53266">PPI</z:chebi> therapy is important for economic reasons, as it may save up to two thirds of daily doses of the drugs, with a considerable containment of drug expenses </plain></SENT>
<SENT sid="8" pm="."><plain>For a long-term disease whose treatment is aimed primarily at symptom control, it is a sensible and cost-effective approach </plain></SENT>
</text></document>